Drug developer spun out of MAPS and renamed from MAPS PBC to Lykos in January 2024, developing MDMA-assisted therapy (midomafetamine) for PTSD. The FDA declined its NDA via a Complete Response Letter in August 2024, requesting an additional Phase 3 trial; Lykos subsequently cut roughly 75% of staff and reorganized while continuing to pursue MDMA for PTSD.
Lykos Therapeutics News 10 articles
- FDA publicly releases Lykos' MDMA complete response letter
- Psychedelic News Roundup: August 16th, 2024
- Denial of Lykos’ MDMA-Assisted PTSD Therapy Followed by Retraction of Related Studies
- FDA Denies Lykos and Requests Another Trial
- Lykos Therapeutics Responds to ICER’s Critique of MDMA Assisted Psychotherapy for PTSD
- Lykos Therapeutics Addresses Concerns Over MDMA Treatment for PTSD
- Pharmala Biotech: CEO Letter To Shareholders
- MDMA is Set for FDA Panel Review on June 4th
- The FDA Accepts MDMA for PTSD Therapy’s New Drug Application
- MAPS Public Benefit Corporation Announces Oversubscribed Series A Financing and Renames to Lykos Therapeutics